| Drug General Information |
| Drug ID |
D0X6XH
|
| Former ID |
DNCL003120
|
| Drug Name |
CM-2395
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Phase 3 |
[1]
|
|---|
| Company |
Cenomed BioSciences
|
| Target and Pathway |
| Target(s) |
D(3) dopamine receptor |
Target Info |
Agonist |
[2]
|
|---|
| Sigma(1)-type opioid receptor |
Target Info |
Agonist |
[2]
|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Agonist |
[2]
|
| D(4) dopamine receptor |
Target Info |
Agonist |
[2]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04024:cAMP signaling pathway
|
|
Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapse
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP2006:miR-targeted genes in squamous cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBaseWP722:Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
GPCR downstream signalingWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCRs, Other
|
| References |
| REF 1 | Pharmaceutical Research Companies Are Developing More Than 300 Medicines to Treat Mental Illnesses. Pharmaceutical Research and Manufacturers of America report.2010. |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) |
|---|
